Phase II trial of 5-fluorouracil and high-dose folinic acid in advanced renal cell cancer.
Fourteen patients with metastatic renal cell carcinoma (RCC) were treated with high-dose folinic acid (HDFA): 200 mg/m2 i.v. and 5-fluorouracil (5-FU): 370 mg/m2 i.v. for 5 consecutive days every 28 days. Severe oral mucositis (WHO grade III-IV) was experienced by two patients, whereas hematological toxicity was mild. No complete or partial remission was observed. Short-lasting stable disease occurred in 8 patients (median = 5 months, range 2-11). This combination does not need further evaluation in patients with RCC.
Zaniboni
A
A
Servizio di Oncologia, Spedali Civili, Brescia, Italy.
Simoncini
E
E
Marpicati
P
P
Montini
E
E
Ferrari
V
V
Marini
G
G
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged
D002955:Leucovorin; D005472:Fluorouracil